Manchester Advanced Trauma Training ## Annual Report 1[st] February 2024 – 31[st] January 2025 ## Contents **Annual Summary of the Charity** ............................................................................................................ 3 **Activity** .................................................................................................................................................... 3 High Acuity Low Occurrence (HALO) Course ...................................................................................... 3 Future plans ........................................................................................................................................ 3 2 | P a g e ## Annual Summary of the Charity Manchester Advanced Trauma Training (MATT) became a Charitable Incorporated Organisation on 10th February 2022. There are five Trustees of the Charity. The object of Manchester Advanced Trauma Training is the advancement of health for public benefit by educating healthcare professionals about major trauma. ## Activity ## High Acuity Low Occurrence (HALO) Course On 7[th] March 2024, a one-day, bespoke cadaveric course was held to train pre-hospital and emergency department doctors and paramedics in the surgical procedures they may be called to do under austere circumstances. 27 people attended. The informal feedback was excellent and MATT continues to receive requests to run the course again. This course formed part of a suite of courses run in the first week of March 2024. MATT partnered with Manchester Trauma, a local company running predominantly orthopaedic trauma courses, to share costs. The specimens, and their cost, was shared across the courses. A modest fee was charged to the participants to ensure there was not a shortfall. Medical technology companies who produce orthopaedic equipment also sponsored the courses. MATT did not take a profit or loss and did not see any cashflow. The aim was to break even, rather than to produce a profit. ## Future plans MATT is run by volunteers with full time healthcare positions within the NHS. It is becoming increasingly challenging to deliver trauma courses. From a financial perspective from MATT has seen increasing costs, particularly of cadaveric specimens, and decreasing study budgets available to healthcare professionals as well as educational budgets available from industry. The volunteers who run the charity or under increasing pressure from their NHS practices and time to run courses is very sparse. The administrative load to running a suite of courses is very large. The future of the charity is uncertain. 3 | P a g e |**Charity Name**|||**No (if any)**|| |---|---|---|---|---| |**Receipts and payments accounts**||||**CC16a**| |**For the period**
**from**|Period start date|**To**|Period end date|| |**Section A Receipts and payments**|**Section A Receipts and payments**|||||| |---|---|---|---|---|---|---| |**A1 Receipts**|**Unrestricted**
**funds**
**to the nearest £**
**- # **
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
420
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**420**
**-**
**-**
**-**
**420**
**- 420**
**-**
**-**
**- 420**|**Restricted**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Endowment**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Total funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**420**
**-**
**-**
**-**
**420**
**- 420**||**Last year**
**to the nearest £**| ||**-**|||||**27,053**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| |**_Sub total_**_(Gross income for_
_AR)_|**-**|||||**27,053**| |||||||| |**A2 Asset and investment sales,**
**(see table).**||||||| ||**-**|||||| ||**-**|||||**-**| |**_Sub total_**|**-**|||||**-**| |**_Total receipts_**
**A3 Payments**||||||| |||||||**27,053**| |||||||| ||420|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| ||**-**|||||**-**| |**_Sub total_ **|**420**|||||**-**| |||||||| |**A4 Asset and investment**
**purchases (see table)**||||||| |**,**|**-**|||||| ||**-**|||||| |**_Sub total_ **|**-**|||||**-**| |**_Total payments_**
**_Net of receipts/(payments)_**
**A5 Transfers between funds**
**A6 Cash funds last year end**
**_Cash funds this year end_**||||||| |||||||**-**| |||||||| ||**- 420**|**-**|**-**|**- 420**||**27,053**| ||**-**|**-**|**-**|**-**||**-**| ||**-**|**-**|**-**|**-**||**-**| ||**- 420**|**-**|**-**|**- 420**||**27,053**| CCXX R1 accounts (SS) 09/12/2025 1 |**Section B Statement of assets and liabilities at the end of the period**|**Section B Statement of assets and liabilities at the end of the period**|**Section B Statement of assets and liabilities at the end of the period**|| |---|---|---|---| |**Categories**
Signed by one or two trustees on
behalf of all the trustees
**B5 Liabilities**
**B3 Investment assets**
**B2 Other monetary assets**
**B4 Assets retained for the**
**charity’s own use**
**B1 Cash funds**|**Details**
**Details**
**_Total cash funds_**
(agree balances with receipts and payments
account(s))
**Details**
**Details**
**Details**
#VALUE!
Signature
#VALUE!|**Unrestricted**
**funds**
**Restricted**
**funds**
**to nearest £**
**to nearest £**
**26,633**
**-**
**-**
**-**
**-**
**-**
**26,633**
**-**
Agreement Error
OK
**Unrestricted**
**funds**
**Restricted**
**funds**
**to nearest £**
**to nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**asset belongs**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**asset belongs**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**liability relates**
**Amount due**
**(optional)**
**-**
**-**
**-**
**-**
**-**
Print Name
Stella Smith
Ian Tyrrell-Marsh|**Endowment**
**funds**
**to nearest £**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||OK| ||||**Endowment**
**funds**
**to nearest £**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**Current value**
**(optional)**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**Current value**
**(optional)**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**-**| ||||**When due**
**(optional)**| ||||| ||||| ||||| ||||| ||||| ||||| ||||Date of
approval| ||#VALUE!|Stella Smith|08/12/2025| ||#VALUE!|Ian Tyrrell-Marsh|08/12/2025| CCXX R2 accounts (SS) 09/12/2025 2